TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 10nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 16nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 18nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 28nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 31nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 39nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 58nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 66nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 66nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 72nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 72nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 81nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 85nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 87nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 88nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 89nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 92nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 95nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 100nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 100nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 110nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 110nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 120nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 120nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 140nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 150nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 160nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 170nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 190nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 210nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 220nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 250nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 250nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 260nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 270nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 270nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 280nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 300nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 360nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 360nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 370nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 400nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 410nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 410nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 470nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 490nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 500nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 520nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 560nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma [258-518,Y502F](Homo sapiens (Human))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 670nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair